Upside case
Bull case
$72+27.8%
BSX would need investors to value it at roughly 21x earnings — about 5x more generous than today's 17x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Boston Scientific Corporation (BSX) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
43
analysts
40 bullish · 0 bearish · 43 covering BSX
Strong Buy
1
Buy
39
Hold
3
Sell
0
Strong Sell
0
Consensus Target
$91
+63.1% vs today
Scenario Range
$17 – $72
Model bear to bull value window
Coverage
43
Published analyst ratings
Valuation Context
16.6x
Forward P/E · Market cap $83.2B
BSX price targets
Three scenarios for where BSX stock could go
Current
~$56
Confidence
74 / 100
Updated
May 1, 2026
Where we are now
Current · $56
Bear
$17
Base
$92
Bull
$72
Market caseClosest to today
Base case
$92+63.9%
At 27x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$17-68.8%
If investor confidence fades or macro conditions deteriorate, a 11x multiple contraction could push BSX down roughly 69% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Boston Scientific Corporation
BSX · NYSEHealthcareMedical - DevicesDecember year-end
Boston Scientific is a global medical device company that develops and manufactures minimally invasive medical technologies for a wide range of conditions. It generates revenue primarily through three segments: Cardiovascular (~45% of sales), MedSurg (~30%), and Rhythm and Neuro (~25%), selling everything from stents and pacemakers to spinal cord stimulators and endoscopic devices. The company's competitive advantage lies in its deep clinical expertise, extensive patent portfolio, and strong physician relationships built over decades—creating high switching costs in a highly regulated industry.
Market Cap
$83.2B
Revenue TTM
$20.1B
Net Income TTM
$2.9B
Net Margin
14.4%
BSX Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
100%Exceptional
12 quarters tracked
Revenue Beat Rate
100%Exceptional
vs consensus estimates
Avg EPS Surprise
+6.1%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$0.75/$0.72
Revenue
$5.1B/$4.9B
Q4 2025
EPS
$0.75/$0.71
Revenue
$5.1B/$5.0B
Q1 2026
EPS
$0.80/$0.78
Revenue
$5.3B/$5.3B
Q2 2026
EPS
$0.80/$0.79
Revenue
$5.2B/$5.2B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $0.75/$0.72 | +3.4% | $5.1B/$4.9B | +3.4% |
| Q4 2025 | $0.75/$0.71 | +5.0% | $5.1B/$5.0B | +1.9% |
| Q1 2026 | $0.80/$0.78 | +2.4% | $5.3B/$5.3B | +0.1% |
| Q2 2026 | $0.80/$0.79 | +1.5% | $5.2B/$5.2B | +0.6% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$22.6B
+12.8% YoY
FY2
$26.1B
+15.2% YoY
EPS Outlook
FY1
$2.88
+49.1% YoY
FY2
$3.18
+10.4% YoY
Trailing FCF (TTM)$3.6B
FCF Margin: 18.1%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
BSX beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
BSX Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $20.1B
Product Mix
Latest annual revenue by segment or product family
Cardiovascular
66.0%
+23.3% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
64.1%
+26.0% YoY
Tap, hover, or focus a slice to inspect segment detail.
Cardiovascular is the largest disclosed segment at 66.0% of FY 2025 revenue, up 23.3% YoY.
UNITED STATES is the largest reported region at 64.1%, up 26.0% YoY.
BSX Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Undervalued
Fair value est. $73 — implies +28.6% from today's price.
Upside to Fair Value
28.6%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
BSX
28.9x
vs
S&P 500
25.1x
+15% premium
vs Healthcare Trailing P/E
BSX
28.9x
vs
Healthcare
22.2x
+30% premium
vs BSX 5Y Avg P/E
Today
28.9x
vs
5Y Average
68.0x
58% discount
Forward PE
16.6x
S&P 500
19.1x
-13%
Healthcare
18.8x
-12%
5Y Avg
—
—
Trailing PE
28.9x
S&P 500
25.1x
+15%
Healthcare
22.2x
+30%
5Y Avg
68.0x
-58%
PEG Ratio
—
S&P 500
1.72x
—
Healthcare
1.53x
—
5Y Avg
—
—
EV/EBITDA
25.1x
S&P 500
15.2x
+65%
Healthcare
14.0x
+79%
5Y Avg
30.7x
-18%
Price/FCF
22.7x
S&P 500
21.1x
+8%
Healthcare
18.6x
+23%
5Y Avg
51.6x
-56%
Price/Sales
4.1x
S&P 500
3.1x
+33%
Healthcare
2.8x
+48%
5Y Avg
6.3x
-34%
Dividend Yield
—
S&P 500
1.87%
—
Healthcare
1.42%
—
5Y Avg
0.07%
—
| Metric | BSX | S&P 500 | Healthcare | 5Y Avg BSX |
|---|---|---|---|---|
| Forward PE | 16.6x | 19.1x-13% | 18.8x-12% | — |
| Trailing PE | 28.9x | 25.1x+15% | 22.2x+30% | 68.0x-58% |
| PEG Ratio | — | 1.72x | 1.53x | — |
| EV/EBITDA | 25.1x | 15.2x+65% | 14.0x+79% | 30.7x-18% |
| Price/FCF | 22.7x | 21.1x | 18.6x+23% | 51.6x-56% |
| Price/Sales | 4.1x | 3.1x+33% | 2.8x+48% | 6.3x-34% |
| Dividend Yield | — | 1.87% | 1.42% | 0.07% |
BSX trades above S&P 500 benchmarks on 3 of 5 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolBSX Financial Health
Verdict
Strong
BSX generates $3.6B in free cash flow at a 18.1% margin.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$20.1B
Revenue Growth
TTM vs prior year
+19.9%
Gross Margin
Gross profit as a share of revenue
69.0%
Operating Margin
Operating income divided by revenue
19.8%
Net Margin
Net income divided by revenue
14.4%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$1.93
Free Cash Flow (TTM)
Cash generation after capex
$3.6B
FCF Margin
FCF as share of revenue — the primary cash quality signal
18.1%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
8.8%
ROA
Return on assets, trailing twelve months
6.9%
Cash & Equivalents
Liquid assets on the balance sheet
$2.0B
Net Debt
Total debt minus cash
$10.4B
Debt Serviceability
Net debt as a multiple of annual free cash flow
2.9× FCF
~2.9 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
12.4%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.0%
Dividend
—
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Current diluted share count
1.5B
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageBSX Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
High Risk
Financial & Corporate Risks
Boston Scientific’s debt has risen sharply, especially after the $14.5B acquisition of Penumbra, pushing leverage ratios above industry peers. The company’s valuation may suffer if earnings growth fails to meet expectations, potentially leading to a significant downside.
High Risk
Integration of Acquisitions
The Penumbra deal adds substantial debt and requires complex integration of operations, technology, and culture. Failure to achieve synergies could result in short‑term dilution and higher operating costs.
High Risk
Competition & Market Dynamics
Rivals such as Medtronic and Abbott are expanding their product lines in key segments, threatening Boston Scientific’s market share in RF and cryoablation. Pricing pressure in critical portfolios like coronary drug‑eluting stents (DES) and coronary restenosis management (CRM) could compress margins.
High Risk
Legal & Regulatory Risks
Healthcare policy shifts and the EU’s Medical Device Regulation (MDR) transitional periods could delay product approvals and increase compliance costs. Regulatory changes may also affect reimbursement rates, impacting revenue streams.
Medium
Product Development & Approval
Delays in obtaining regulatory approvals or market acceptance of new technologies, such as the FARAPULSE pulsed field ablation system, could slow growth. Successful launches are critical, but any setbacks would reduce expected revenue contributions.
Medium
Macroeconomic Factors
Inflation, geopolitical tensions, and supply‑chain disruptions could raise manufacturing costs and delay product deliveries. These macro risks may erode profitability and affect cash flow.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why BSX Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Market Leadership & Innovation
Boston Scientific dominates cardiology, electrophysiology, endoscopy, urology, neuromodulation, and oncology segments. The launch of the FARAPULSE Pulsed Field Ablation (PFA) system further strengthens its competitive edge.
Strategic Acquisitions
The company follows a disciplined acquisition strategy, investing significantly to broaden its product portfolio and market reach. These acquisitions have consistently added complementary technologies and customer bases.
Strong Revenue & Margin Growth
Projected fiscal 2025 revenue growth is 12.5%–14.5%, with a 2024 gross profit margin of 68.4%. Analysts also project earnings growth of 13.33% for the coming year.
Global Expansion into Emerging Markets
Boston Scientific is actively expanding into China, Japan, and the EMEA region, diversifying its revenue streams. This global footprint strengthens its market presence and reduces reliance on any single geography.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
BSX Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$55.98
52W Range Position
0%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$55.89
+0.2% from the low
52-Week High
$109.50
-48.9% from the high
1 Month
-10.56%
3 Month
-27.90%
YTD
-40.9%
1 Year
-46.3%
3Y CAGR
+2.8%
5Y CAGR
+5.4%
10Y CAGR
+9.9%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
BSX vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
16.6x
vs 14.1x median
+18% above peer median
Revenue Growth
+12.8%
vs +3.8% median
+234% above peer median
Net Margin
14.4%
vs 12.9% median
+11% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
BSX BSX Boston Scientific Corporation | $83.2B | 16.6x | +12.8% | 14.4% | Buy | +63.1% |
MDT MDT Medtronic plc | $99.7B | 14.1x | +2.5% | 13.0% | Buy | +40.8% |
EW EW Edwards Lifesciences Corporation | $47.8B | 27.6x | +9.9% | 17.6% | Buy | +16.4% |
SYK SYK Stryker Corporation | $113.1B | 19.7x | +9.9% | 12.9% | Buy | +36.7% |
ZBH ZBH Zimmer Biomet Holdings, Inc. | $16.3B | 9.8x | +3.8% | 9.1% | Hold | +17.9% |
BDX BDX Becton, Dickinson and Company | $52.2B | 11.5x | +2.3% | 8.0% | Buy | +19.9% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
FAQ
7 questionsBSX Investor Questions
Common questions answered from live analyst data and company financials.
01Is Boston Scientific Corporation (BSX) stock a buy or sell in 2026?
Boston Scientific Corporation (BSX) is rated Buy by Wall Street analysts as of 2026. Of 43 analysts covering the stock, 40 rate it Buy or Strong Buy, 3 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $91, implying +63.1% from the current price of $56. The bear case scenario is $17 and the bull case is $72.
02What is the BSX stock price target for 2026?
The Wall Street consensus price target for BSX is $91 based on 43 analyst estimates. The high-end target is $120 (+114.4% from today), and the low-end target is $60 (+7.2%). The base case model target is $92.
03Is Boston Scientific Corporation (BSX) stock overvalued in 2026?
BSX trades at 16.6x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Boston Scientific Corporation (BSX) stock in 2026?
The primary risks for BSX in 2026 are: (1) Financial & Corporate Risks — Boston Scientific’s debt has risen sharply, especially after the $14. (2) Integration of Acquisitions — The Penumbra deal adds substantial debt and requires complex integration of operations, technology, and culture. (3) Competition & Market Dynamics — Rivals such as Medtronic and Abbott are expanding their product lines in key segments, threatening Boston Scientific’s market share in RF and cryoablation. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Boston Scientific Corporation's revenue and earnings forecast?
Analyst consensus estimates BSX will report consensus revenue of $22.6B (+12.8% year-over-year) and EPS of $2.88 (+49.1% year-over-year) for the upcoming fiscal year. The following year, analysts project $26.1B in revenue.
06When does Boston Scientific Corporation (BSX) report its next earnings?
A confirmed upcoming earnings date for BSX is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Boston Scientific Corporation generate?
Boston Scientific Corporation (BSX) generated $3.6B in free cash flow over the trailing twelve months — a free cash flow margin of 18.1%. BSX returns capital to shareholders through and share repurchases ($0 TTM).